New option for treating active rheumatoid arthritis
In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself ...
Jun 6, 2019
0
134